FDA-cleared profile

EFAI RTSUITE CT HCAP-Segmentation System

Ever Fortune.AI Co., Ltd. · Radiotherapy Planning Imaging · FDA-cleared (510(k))

Authorized purpose: EFAI HCAPSeg assists trained radiation-oncology professionals with radiation-treatment planning by providing initial deep-learning contours of organs at risk on non-contrast CT images for transfer to a DICOM-compliant treatment-planning system.

Clinical role
Radiation-treatment planning, image registration, contouring, dose calculation, or plan review support under qualified professional control.
Images and patients
Radiotherapy Planning Imaging · Adult organs at risk on non-contrast CT during radiation-treatment planning
Key limitation
Keep in mind: Automated contours, plans, registrations, dose values, or other outputs require qualified review, editing, commissioning, and local validation before clinical use.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: EFAI HCAPSeg assists trained radiation-oncology professionals with radiation-treatment planning by providing initial deep-learning contours of organs at risk on non-contrast CT images for transfer to a DICOM-compliant treatment-planning system.
  • Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: Adult organs at risk on non-contrast CT during radiation-treatment planning Input: Supported CT, MR, PET, or other DICOM image data, structures, prescriptions, and treatment-planning inputs within the exact submission.
  • Who uses it?Intended users: Radiation oncologists, medical physicists, dosimetrists, and other trained radiation-treatment professionals.
  • What does the software produce?Output: Contours, registered images, dose distributions, plans, measurements, or exported treatment-planning objects for professional review and approval.
  • What is its most important limitation?Key limitation: Automated contours, plans, registrations, dose values, or other outputs require qualified review, editing, commissioning, and local validation before clinical use.

Clinical takeaway. Clinical role: EFAI HCAPSeg assists trained radiation-oncology professionals with radiation-treatment planning by providing initial deep-learning contours of organs at risk on non-contrast CT images for transfer to a DICOM-compliant treatment-planning system.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports a standalone evaluation on 157 non-contrast U.S. CT cases independent of development training and internal testing, with ground truth from three board-certified radiation oncologists. Overall mean DSC was 0.83; non-inferiority tests against a comparison device met the primary endpoint, with mean DSC 0.80, 0.90, and 0.90 in Head & Neck, Chest, and Abdomen & Pelvis. OARs unique to the device, tested for superiority to a pre-specified value, had mean DSC 0.82. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
EFAI HCAPSeg assists trained radiation-oncology professionals with radiation-treatment planning by providing initial deep-learning contours of organs at risk on non-contrast CT images for transfer to a DICOM-compliant treatment-planning system.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Radiation-treatment planning, image registration, contouring, dose calculation, or plan review support under qualified professional control.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported CT, MR, PET, or other DICOM image data, structures, prescriptions, and treatment-planning inputs within the exact submission.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Contours, registered images, dose distributions, plans, measurements, or exported treatment-planning objects for professional review and approval.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Radiation-oncology treatment-planning or image-review environments.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Radiation oncologists, medical physicists, dosimetrists, and other trained radiation-treatment professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Automated contours, plans, registrations, dose values, or other outputs require qualified review, editing, commissioning, and local validation before clinical use.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports a standalone evaluation on 157 non-contrast U.S. CT cases independent of development training and internal testing, with ground truth from three board-certified radiation oncologists. Overall mean DSC was 0.83; non-inferiority tests against a comparison device met the primary endpoint, with mean DSC 0.80, 0.90, and 0.90 in Head & Neck, Chest, and Abdomen & Pelvis. OARs unique to the device, tested for superiority to a pre-specified value, had mean DSC 0.82. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The dataset used in this study comprised 157 non-contrast CT cases consecutively collected from the United States (U.S.), all meeting the established inclusion criteria. All data used during the standalone performance evaluation was acquired independently from product development training and internal testing." … "Each of the OAR contouring was generated by three board-certified radiation oncologists as the ground truth (GT).". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports a standalone evaluation on 157 non-contrast U.S. CT cases independent of development training and internal testing, with ground truth from three board-certified radiation oncologists. Overall mean DSC was 0.83; non-inferiority tests against a comparison device met the primary endpoint, with mean DSC 0.80, 0.90, and 0.90 in Head & Neck, Chest, and Abdomen & Pelvis. OARs unique to the device, tested for superiority to a pre-specified value, had mean DSC 0.82. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The dataset used in this study comprised 157 non-contrast CT cases consecutively collected from the United States (U.S.), all meeting the established inclusion criteria. All data used during the standalone performance evaluation was acquired independently from product development training and internal testing." … "Each of the OAR contouring was generated by three board-certified radiation oncologists as the ground truth (GT).". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No exact-submission and version-linked sensitivity endpoint is promoted; candidate or product-family values were not substituted.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No exact-submission and version-linked specificity endpoint is promoted; candidate or product-family values were not substituted.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

FDA submission-specific verification and validation evidence for K231928

  • DesignFDA 510(k) regulatory decision material and submission-specific verification or validation evidence for K231928; this is regulatory evidence, not an independent clinical effectiveness study.
  • PopulationThe labeled population, anatomy, images, and test materials described in the exact FDA decision material for K231928; a broader clinical population is not established here.
  • Scopeexact submission
  • Tested versionEFAI RTSUITE CT HCAP-Segmentation System (K231928)
  • IndependenceSponsor or vendor study

K231928

The exact FDA material is submission-specific and should not be generalized to other versions, enabled options, sites, protocols, or clinical outcomes.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported CT, MR, PET, or other DICOM image data, structures, prescriptions, and treatment-planning inputs within the exact submission.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K231928: EFAI RTSUITE CT HCAP-Segmentation System

  2. Routing

    Source context, not route validation: The exact FDA package describes DICOM-format CT image input and organ-at-risk contours output in DICOM format as RTSTRUCT, used with a DICOM-compliant treatment planning system to review and edit results. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "The device receives CT images in DICOM format as input and automatically generates the contours of OARs, which are stored in DICOM format and in RTSTRUCT modality." … "must be used in conjunction with a DICOM-compliant treatment planning system to review and edit results.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA 510(k) decision material K231928: EFAI RTSUITE CT HCAP-Segmentation System

  3. AI processing

    Source context, not route validation: The exact FDA package describes EFAI HCAPSeg as installed on a specialized server supporting deep learning processing, with a recommended deployment environment in a local network with an existing hospital-grade IT system. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "The deployment environment is recommended to be in a local network with an existing hospital-grade IT system in place." … "EFAI HCAPSeg should be installed on a specialized server supporting deep learning processing.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA 510(k) decision material K231928: EFAI RTSUITE CT HCAP-Segmentation System

  4. Returned objects

    Source context, not route validation: Contours, registered images, dose distributions, plans, measurements, or exported treatment-planning objects for professional review and approval.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K231928: EFAI RTSUITE CT HCAP-Segmentation System

  5. Viewer/worklist/report

    Unresolved route: Contours, registered images, dose distributions, plans, measurements, or exported treatment-planning objects for professional review and approval.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K231928: EFAI RTSUITE CT HCAP-Segmentation System

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes EFAI HCAPSeg as installed on a specialized server supporting deep learning processing, with a recommended deployment environment in a local network with an existing hospital-grade IT system. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The deployment environment is recommended to be in a local network with an existing hospital-grade IT system in place." … "EFAI HCAPSeg should be installed on a specialized server supporting deep learning processing.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact FDA package describes DICOM-format CT image input and organ-at-risk contours output in DICOM format as RTSTRUCT, used with a DICOM-compliant treatment planning system to review and edit results. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The device receives CT images in DICOM format as input and automatically generates the contours of OARs, which are stored in DICOM format and in RTSTRUCT modality." … "must be used in conjunction with a DICOM-compliant treatment planning system to review and edit results.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Security
Ever Fortune.AI's investor information-security policy page states an implemented information security management system covering confidentiality, integrity, and availability, with security training and measurement targets; the page states the company has completed ISO 27001 certification and holds ISO/IEC 27701 PII-processor certification after independent third-party audit. The company's certification-milestones page lists ISO/IEC 27001:2022, ISO 22301:2019, ISO/IEC 27018:2019, and ISO/IEC 27017:2015.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement; certificates were not read. Applicant name variants (including uppercase and punctuation variants of Ever Fortune.AI Co., Ltd.) are bridged via the vendor's EFAI product naming and the owning domain everfortuneai.com.tw. Exact-release scope is not established.

Workflow role

Radiation-treatment planning, image registration, contouring, dose calculation, or plan review support under qualified professional control.

exact submission · checked 2026-09-04

Submission-anchored workflow summary, not a local acceptance or deployment result.

Input

Supported CT, MR, PET, or other DICOM image data, structures, prescriptions, and treatment-planning inputs within the exact submission.

exact submission · checked 2026-09-04

Exact supported inputs and protocol limits must be confirmed from the complete labeling.

Output

Contours, registered images, dose distributions, plans, measurements, or exported treatment-planning objects for professional review and approval.

exact submission · checked 2026-09-04

Output review, editing, approval, export, and downstream use remain release- and site-specific.

Deployment evidence

Exact deployment topology and operational boundaries remain unestablished.

exact submission · checked 2026-09-04

Confirm hosting, PHI flow, retention, access, updates, downtime, and support obligations before procurement or clinical use.

Integration evidence

Exact local interfaces, identity matching, routing, display, reporting, and fallback behavior remain unestablished.

exact submission · checked 2026-09-04

Validate the local workflow against the exact release and enabled options.

Vendor family context

Current vendor material is product-family context for K231928 only; exact release, enabled options, deployment, security, interoperability, pricing, and local workflow require confirmation.

product family · checked 2026-09-04

Vendor material is not exact-release evidence unless that linkage is separately proven.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K231928
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Adult organs at risk on non-contrast CT during radiation-treatment planning
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-09-25
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
31Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not applicable - checked 2026-09-04 - Not applicable

    CMS coverage-index context was checked, but no product-specific coverage or reimbursement determination is inferred.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

9 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K231928: EFAI RTSUITE CT HCAP-Segmentation System

    U.S. Food and Drug Administration - Published 2023-09-25 - Accessed 2026-09-04

    Scope: identity, productIdentity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Radiation Oncology Model

    Centers for Medicare & Medicaid Services - Accessed 2026-09-02

    Scope: reimbursement, radiationTherapyPaymentContext

  8. Ever Fortune radiation oncology family context

    Ever Fortune.AI - Accessed 2026-09-04

    Scope: productFamilyContext

  9. Ever Fortune.AI: Information Security Policy (ISO 27001 / ISO 27701)

    Ever Fortune.AI - Accessed 2026-10-27

    Scope: security

Research history

  1. K231928 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252190

DeepBT Detector-Plus

Aitewan Biomedical Technology, Inc.

Authorized purpose: DeepBT Detector-Plus provides initial gross-tumor-volume contours on T1-weighted contrast-enhanced and optional T2-weighted MR images for radiation-treatment planning in adults with the labeled brain tumors.

Modality
Radiotherapy Planning Imaging
Anatomy
Brain tumors, including metastases, meningiomas, and acoustic neuromas
Decision
2026-04-10
FDA-cleared K252304

syngo.via RT Image Suite VC10

Varian Medical Systems, Inc.

Authorized purpose: syngo.via RT Image Suite VC10 provides three-dimensional and four-dimensional multimodality visualization, registration, fusion, contouring, and planning support for radiation-treatment preparation.

Modality
Radiotherapy Planning Imaging
Anatomy
Brain, pelvis, thorax, abdomen, targets, organs at risk, and moving tumors or organs
Decision
2026-03-18
FDA-cleared K252188

EMLA (Elekta Evo); EMLA (VersaHD); EMLA (Elekta Harmony Pro); EMLA (Elekta Infintiy); EMLA (Elekta Harmony); EMLA (Elekta Synergy)

Elekta Solutions AB

Authorized purpose: The EMLA family delivers external-beam radiation therapy for adult and pediatric patients with benign, malignant, or metastatic disease. Authorized techniques vary by model: Synergy and Harmony include conventional and fractionated delivery; Infinity and Harmony Pro add SBRT/SABR; Versa HD and Evo also support SRS and specified functional disorders.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2026-01-15
FDA-cleared K250427

TAIMedImg DeepMets

Taiwan Medical Imaging Co., Ltd.

Authorized purpose: TAIMedImg DeepMets assists trained professionals by providing initial gross-tumor-volume contours on axial contrast-enhanced T1 brain MR images for radiation-treatment planning in adults with known brain metastases; the contours require thorough review and are not a replacement for manual contouring.

Modality
Radiotherapy Planning Imaging
Anatomy
Brain metastases in adults
Decision
2025-05-28

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history